# A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

> **NCT03970382** · PHASE1 · SUSPENDED · sponsor: **PACT Pharma, Inc.** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** NeoTCR-P1 adoptive cell therapy
- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** IL-2

## Key facts

- **NCT ID:** NCT03970382
- **Lead sponsor:** PACT Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-07-03
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03970382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03970382, "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03970382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*